Research Funding

Caspar Wistar Fellows Program

Deadline: January 29, 2018
Download the RFA

The Caspar Wistar Fellows Program (Program) will recruit two exceptional post-doctoral fellows as independent investigators, creating a springboard for the Caspar Wistar Fellows (Fellows) to facilitate a subsequent faculty appointment and join the next generation of scientific leaders.

The Wistar Institute Vaccine & Immunotherapy Center and The Wistar Institute Cancer Center comprise a group of 35 exceptional faculty dedicated to fundamental and translational research in cancer biology, immunology, virology and genetics. Fellows will be provided their own research space, resources and support needed to run their own labs and pursue their own independent research agenda. Fellows will be appointed for a three-year term with the possibility of extending an additional one to two years.  Two Fellows will be recruited in 2018: one Fellow with a cancer focus that will join Wistar’s NCI-designated Cancer Center and one with a vaccine/immunology focus that will join Wistar’s Vaccine & Immunotherapy Center.

Program candidates must demonstrate intellectual drive and superior research credentials, a particularly creative and innovative research plan, strong communication skills, and the motivation and demonstrated capacity to conduct research with minimal supervision. Candidates whose work is based on biological principles, but incorporates concepts from diverse fields, are encouraged to apply. Candidates must hold a Ph.D., M.D., or equivalent degree. Candidates are expected to have a strong publication.

The search committees will be led by established Wistar faculty and program leaders who are ideally suited to recognize how well a prospective candidate fits within the overall Wistar mission, and its specific programs. Interested candidates should electronically submit a cover letter, curriculum vitae, a description of previous research (one page), a concise statement of research plans (up to two pages), reprints of four publications and the names of three references to the attention of Maria Colelli, Search Coordinator Caspar Wistar Fellows Program (   Please see our ads online in Nature and Science magazines. Applications will be evaluated by January 29, 2018.   Interviews will be held beginning in April 2018.


RFP for Therapeutic Development Opportunities for Neuroprotection and Neuroregeneration in Multiple Sclerosis

Deadline:  December 20, 2017

The National Multiple Sclerosis Society invests in promising research to drive breakthroughs that will stop MS, restore function and end MS forever. As part of its commitment to addressing the needs of individuals affected by MS, the Society invites proposals to establish research partnerships with Fast Forward, LLC to accelerate and support development of therapeutic strategies relevant to MS.

  • The National MS Society has released a Request for Proposals to fund drug development opportunities for therapies promoting neuroprotection and repair. New treatment strategies are needed to stop disease worsening by preventing neurodegeneration and reversing neuronal damage so that lost function can be restored. Although it is recognized that animal models of MS provide only limited insight into the pathophysiology of neurodegenerative process, studies to evaluate impact on demyelination, remyelination, neuroprotection, neural plasticity, and repair are considered appropriate for this RFP
    • Pre-Applications will be accepted starting November 8, 2017.
    • Final date for acceptance of preapplications: December 6, 2017.
    • Full Proposals will be due no later than December 20, 2017.

Areas of high impact for this program include:
* Therapeutic approaches that directly promote remyelination and/or neuroprotection (including stimulation of endogenous repair and cell-based approaches)
* Proof of concept studies with repurposed FDA-approved therapies that have defensible intellectual property or strong commercial viability

Research areas supported by this program include, but are not limited to:
* Early-stage target validation
* Optimization of pre-clinical compounds
* PK/ADMET studies for valid compounds in development
* Imaging studies to measure target occupancy or target-related pharmacodynamic effects that could support a future clinical trial

This RFP is open to global commercial organizations and not-for-profit research institutions collaborating with a commercial organization. Consistent with our goal to support research and development conducted with a high level of quality control typical of the pharmaceutical industry, proposals from not-for-profit institutions will be considered if a majority of the work is conducted at reputable Contract Research Organizations with appropriate expertise relevant to the proposal.

Read more about this opportunity and how to apply.

OnPAR Funding for Scored But Not Awarded NIH Proposals

We would like to inform you about a new initiative called OnPAR (Online Partnership to Accelerate Research).  This was launched by Leidos Life Sciences in March, 2016.  It is a partnership with NIH that offers a new paradigm to provide funding for highly scored but unfunded NIH applications by matching them with interested non-government organizations (NGOs).  Several different scientific areas have previously been funded using this approach, and OnPar has now expanded to include pain research projects.

If you have submitted an application to NIH for pain-related research that was not funded, this may be of interest to you.  If you would like to have your application considered by OnPAR , please visit: for more information.

Additional information from OnPAR:

The application process will take 5 minutes – here:

  1. Basic Registration – here (administrators can also submit for investigators)
  2. Submission of Public Abstract (in English): This is the public abstract that is submitted with your application
  3. Submission of Applications, Peer-Review, and NDA: if there is a match (funders review for interest), then, we request the full application (in original language), the peer-review (in original language) received from the agency (or other agencies) and a signed Non Disclosure Agreement (we provide).  We don’t require investigators to re-write the unfunded application.

Once potential funders review, they will contact the investigator directly to discuss a partnership and funding.

It is free for all investigators to submit their material.

Please register here to receive updates about OnPAR.

Note that OnPAR has also identified other therapeutics areas of interest:

  • Cardiology, Hematology, Oncology, Women’s Healthcare, Gynecological Therapy, Men’s Health, Ophthalmology, Radiology
  • Diabetes and Complications
  • Infectious Diseases
  • Heart & Kidney
  • Cancer: Breast, Lung, Prostate, Brain, Colon, Bone, and others
  • Neurosciences (AD, PD, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Migraine, Huntington’s)
  • Rheumatoid arthritis, Psoriasis, Systemic lupus erythematosus, Crohn’s disease, Ulcerative colitis, Ankylosing spondylitis, Psoriatic arthritis, Lupus nephritis, Atopic dermatitis
  • Devices
  • Respiratory (COPD, Asthma)
  • Osteoarthritis, Gastroenterology, Endocrine, Heart failure, Neurology
  • Rare Diseases –many: Cystinosis, NF, Epidermosis Bullosa, Huntington, PSP, Alopecia Areata
  • Animal Health

Also of interest are Discovery & Development Platforms:

  • Cell & Gene Therapy, epigenetics, precision medicine, cell & protein science, chemistry and DMPK, and others

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L   in the message body of the email – You will receive a confirmation email if successful. If you have problems contact   301-435-1309